On August 16, 2022 Beijing’s SinocellTech reported that its anti-CD20 McAb, ripertamab, proved non-inferiority to Genentech’s rituximab (Rituxan) in a China Phase III trial (Press release, Sinocelltech, AUG 16, 2022, View Source [SID1234618453]). The trial enrolled 364 patients with primary diffuse large B-cell lymphoma (DLBCL) . The Objective Response Rate was 94% in both cohorts with safety events also very similar. In 2018, SinocellTech out-licensed rights for ripertamab to CSPC Pharma in a deal worth up to $98 million plus sales milestones. SinocellTech’s pipeline consists of 23 products including 21 novel differentiated drugs and two biosimilars.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!